The article reviews the current therapeutic strategies for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD), which has replaced the previous term Nonalcoholic Fatty Liver Disease (NAFLD) to better reflect its association with metabolic alterations and increased cardiovascular risk. Lifestyle modifications, including proper nutrition and regular physical activity, are the cornerstone of treatment. Nutraceuticals such as silymarin, berberine, curcumin, *Nigella sativa*, *Ascophyllum nodosum*, *Fucus vesiculosus*, vitamin E, coenzyme Q10, and Omega-3 have shown potential benefits in improving metabolic alterations and hepatic steatosis. However, more long-term efficacy and safety data are needed. Innovative therapies, such as incretins and PCSK9 inhibitors, have also shown promise in managing MAFLD and its associated comorbidities. The review highlights the need for tailored therapies to address the cardiovascular risk factors associated with MAFLD and improve liver function.The article reviews the current therapeutic strategies for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD), which has replaced the previous term Nonalcoholic Fatty Liver Disease (NAFLD) to better reflect its association with metabolic alterations and increased cardiovascular risk. Lifestyle modifications, including proper nutrition and regular physical activity, are the cornerstone of treatment. Nutraceuticals such as silymarin, berberine, curcumin, *Nigella sativa*, *Ascophyllum nodosum*, *Fucus vesiculosus*, vitamin E, coenzyme Q10, and Omega-3 have shown potential benefits in improving metabolic alterations and hepatic steatosis. However, more long-term efficacy and safety data are needed. Innovative therapies, such as incretins and PCSK9 inhibitors, have also shown promise in managing MAFLD and its associated comorbidities. The review highlights the need for tailored therapies to address the cardiovascular risk factors associated with MAFLD and improve liver function.